

2022 HPV VACs Data Definitions

Healthcare systems will be required to submit updates to the appropriate quality measure(s) below at three intervals throughout the project, paying careful attention to the reporting and measurement periods. Healthcare systems will report combined results for all clinics participating in the project. Please note these data definitions are subject to change.

HPV VACCINATION QUALITY MEASURES

HPV VACCINATION INITIATION QUALITY MEASURE DESCRIPTION

Percentage of adolescents 9-13 years of age who started the HPV vaccine series. You may separate by sex or report combined.

DENOMINATOR: ELIGIBLE PATIENTS

Include adolescents who were aged 9-13 with at least one reportable medical visit during the 12-month measurement period. Group eligible patients using the following age ranges: 9-10, 11-12, and 13. See exclusions below.

Exclusions

• Exclude dental or other non-medical visits. Medical visits do include well-child visits and sick visits.

NUMERATOR: ELIGIBLE PATIENTS WHO STARTED THE HPV VACCINE SERIES

Include eligible patients who have ever received at least one dose of the HPV vaccine. Group eligible patients using the following age ranges: 9-10, 11-12, and 13.

- Include eligible patients who have also received their 2nd dose.
- · Include eligible patients who have received doses of the vaccine even if it was before the project period.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- This information should be accessed via a EHR or population healthcare system. For information on manual chart audits, contact your ACS staff
 partner.

HPV VACCINATION COMPLETION QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 9-13 who completed the HPV vaccine series. You may separate by sex or report combined.

DENOMINATOR: ELIGIBLE PATIENTS

Include adolescents who were aged 9-13 with at least one reportable medical visit during the 12-month measurement period. Group eligible patients using the following age ranges: 9-10, 11-12, and 13. See exclusions below.

Exclusions

Exclude dental or other non-medical visits. Medical visits do include well-child visits and sick visits.

NUMERATOR: ELIGIBLE PATIENTS WHO HAVE COMPLETED THE HPV VACCINE SERIES

Include eligible patients who have *ever* received two doses of the HPV vaccine separated by at least 5 months. Group eligible patients using the following age ranges: 9-10, 11-12, and 13.

· Include all eligible patients who received doses of the vaccine even if it was before the project period.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- The numerator of eligible patients for completion should not exceed the numerator of eligible patients for initiation.
- This information should be accessed via a EHR or population healthcare system. For information on manual chart audits, contact your ACS staff partner.

cancer.org 1.800.227.2345



2022 HPV VACs **Data Definitions**

MENINGOCOCCAL CONJUGATE QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 11-13 who have received the meningococcal conjugate (MenACWY) vaccine. You may separate by sex or report combined.

NUMERATOR: ELIGIBLE PATIENTS WHO HAVE RECEIVED THE MENINGOCOCCAL VACCINE

Include eligible patients who have ever received the meningococcal conjugate vaccine. Group eligible patients using the following age ranges: 11-12, and 13. See exclusions below.

Exclusions

• Exclude Meningococcal B vaccines from calculation.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- This information should be accessed via a EHR or population healthcare system. For information on manual chart audits, contact your ACS staff partner.

TDAP QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 11-13 who received the Tdap vaccine. You may separate by sex or report combined.

DENOMINATOR: ELIGIBLE PATIENTS

Include adolescents who were aged 11-13 with at least one reportable medical visit during the 12-month measurement period. Group eligible patients using the following age ranges: 11-12, and 13. See exclusions below.

Exclusions

Exclude dental or other non-medical visits. Medical visits do include well-child visits and sick visits.

NUMERATOR: ELIGIBLE PATIENTS WHO HAVE RECEIVED THE TDAP VACCINE

Include eligible patients who have ever received the Tdap vaccine. Group eligible patients using the following age ranges: 11-12, and 13.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- This information should be accessed via a EHR or population healthcare system. For information on manual chart audits, contact your ACS staff partner.